Kyowa Kirin Co., Ltd.

Riken Corporation

Kyowa Hakko Kirin Co., Limited

Kaname Kimura

Shigeyuki Yokoyama

Yasuhisa Shiraishi

Kensaku Sakamoto

Yuji Yamazaki

Akiko Matsumoto

Tatsuo Yanagisawa

Akifumi Kato

Masakazu Homma

Yoshimi Yamaguchi

Kazumasa Ohtake

Tsuguo Kubota

Shinya Ogawa

Kiyoshi Shimizu

Tsuyoshi Yamada

Akiko Hariguchi

Yuko Ube

The present invention relates to a monoclonal antibody or antibody fragment thereof as a human IgG antibody including at least one lysine derivative in a constant region of the human IgG antibody; a modified antibody or antibody fragment thereof, wherein the lysine derivative is modified; a nucleic acid including a nucleotide sequence encoding the antibody or antibody fragment thereof; a vector including the nucleic acid; a transformed cell obtained by introducing the vector into a host cell; a method for producing the antibody or antibody fragment thereof; and a composition containing the antibody or antibody fragment thereof.

Antibody with non-natural amino acid introduced therein

The present invention relates to an antibody specifically binding to human growth arrest specific 6 (hGas6). Specifically, the present invention relates to a monoclonal antibody or an antibody fragment thereof which binds to at least one of amino acid residues at positions 314, 315, and 316 of human Gas6, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment, a transformed cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment, a reagent for detection or assay of Gas6, comprising the antibody or the antibody fragment, a therapeutic agent or a diagnostic agent for a Gas6-related disease, comprising the antibody or the antibody fragment as an active ingredient, and use of the antibody or the antibody fragment for the production of a therapeutic agent or a diagnostic agent for a Gas6-related disease.

Anti human Gas6 monoclonal antibody

The present invention provides an anti-BMP9 (Bone morphogenetic protein-9) monoclonal antibody or an antibody fragment thereof binding to human BMP9, a hybridoma producing the antibody or the antibody fragment, a DNA encoding the antibody or the antibody fragment, a vector comprising the DNA, a transformant obtained by introduction of the vector, a method for preparing the antibody or the antibody fragment using the hybridoma or the transformant, and a therapeutic agent comprising the antibody or the antibody fragment as an active ingredient. Further, the present invention provides a pharmaceutical composition comprising the antibody or the antibody fragment as an active ingredient for the treatment of anemia such as renal anemia, cancer anemia or the like, and a method for treating anemia such as renal anemia, cancer anemia or the like using the same.

Pharmaceutical agent comprising anti-BMP9 antibody as active ingredient for treatment of anemia such as renal anemia and cancer anemia

Growing community of inventors

Tokyo, Japan

Kaname Kimura